Shots:

• Scenic to receive ~$375M that includes up front- milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech
• The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas
• Scenic’s data warehouse of genetic modifiers and its Cell-Seq platform enables the development of potential disease-modifying therapies for devastating diseases with an in-house focus on inherited rare diseases and immuno-oncology/inflammation

­ Ref: PRNewswire | Image: Stat